Multiple Sclerosis

Sativex for the management of multiple sclerosis symptoms

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain